Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Anika Therapeutics Q3 Sales $41.47M Beat $38.27M Estimate

Author: Benzinga Newsdesk | November 02, 2023 05:06pm
Anika Therapeutics (NASDAQ:ANIK) reported quarterly sales of $41.47 million which beat the analyst consensus estimate of $38.27 million by 8.35 percent. This is a 2.98 percent increase over sales of $40.26 million the same period last year.

Posted In: ANIK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist